



News Release

HYDERABAD, INDIA (11 Nov 2025) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter and half year ended 30 Sept 2025. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 11 Nov 2025 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

| | Quarter ended | | | Period ended | | Year ended |
|--|---------------|-----------|-----------|--------------|-----------|------------|
| | 30-Sep-25 | 30-Jun-25 | 30-Sep-24 | 30-Sep-25 | 30-Sep-24 | 31-Mar-25 |
| Revenue | 46.97 | 24.67 | 66.09 | 71.64 | 116.23 | 175.53 |
| R&D and Operational expenses | 806.90 | 526.15 | 547.82 | 1,333.05 | 863.26 | 1,724.29 |
| Depreciation and Amortisation | 13.17 | 13.68 | 14.55 | 26.85 | 29.42 | 58.22 |
| Finance cost | - | - | 0.16 | - | 0.39 | 0.47 |
| Total expenses | 820.07 | 539.83 | 562.52 | 1,359.91 | 893.06 | 1,782.98 |
| Exceptional items (insurance claim received) | - | - | - | - | - | - |
| Tax | - | - | - | - | - | - |
| Profit/(Loss) After Tax for the period/year | (773.10) | (515.17) | (496.44) | (1,288.27) | (776.84) | (1,607.45) |
| Other comprehensive income | 0.85 | (0.51) | (0.05) | 0.34 | (0.09) | (5.83) |
| Total comprehensive income | (772.25) | (515.68) | (496.48) | (1,287.93) | (776.93) | (1,613.28) |
| Paid up equity capital | 227.47 | 218.07 | 218.07 | 227.47 | 218.07 | 218.07 |
| Earnings per share of Rs.1 each (EPS) | (3.48) | (2.36) | (2.27) | (5.80) | (3.56) | (7.37) |

- (a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
- (b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.
- (c) Clinical development pipeline:
- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026.
 - SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026.
 - SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026.
 - SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026.
 - SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026.
- (d) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 17 patents during the period covering countries Australia, Brazil, EPOA, EPO, India, Japan, New Zealand, South Africa, Thailand and USA.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India

Tel: 9140 2354 1142 / 1152 Email: info@suven.com